The Technology Development Board (TDB), under the Department of Science and Technology (DST), is providing financial support to S3V Vascular Technologies Limited for the integrated manufacturing of mechanical thrombectomy kits used in acute ischemic stroke treatment. This initiative aims to establish India's first neurointervention integrated manufacturing plant in Chennai, producing a complete suite of neurointervention devices, reducing reliance on expensive imports, and improving affordability and accessibility of stroke care. S3V Vascular intends to integrate its devices into government programs like Ayushman Bharat and collaborate with hospitals for training interventionalists. The project aligns with the national goal of making India a global hub for affordable, high-end medical technology. The company is also pursuing CE and USFDA approvals to expand access to stroke care solutions globally.
Key Entities Referenced
Ministry of Science Technology TDBDST: Government ministry supporting the development of medical technology.
Breakthrough in Stroke Care: The supported project focused on advancing stroke treatment.
India: The country where the indigenous thrombectomy device is being developed and manufactured.
Indigenous Thrombectomy Device: India's first locally developed device for thrombectomy.
S3V Vascular Technologies: The company developing and manufacturing the thrombectomy device. Also referred to as Ms S3V Vascular Technologies Limited and Ms S3V Vascular Technologies Ltd.
Technology Development Board TDB: The board within the Department of Science and Technology DST that is providing financial support to S3V Vascular Technologies.
Department of Science and Technology DST: The government department overseeing the Technology Development Board TDB.
Integrated Manufacturing of Mechanical Thrombectomy Kit for Treatment of Acute Ischemic Stroke: The title of the project receiving financial support.
Acute Ischemic Stroke: The specific type of stroke the thrombectomy kit is designed to treat.
Medical Devices Park, Oragadam, Sriperumbudur Chennai: The location of the state-of-the-art upstream integrated manufacturing facility.
Mechanical Thrombectomy Kit: A life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion.
Ayushman Bharat: A government reimbursement program targeted for integration of S3V devices.
2 Billion USD: The estimated domestic market size that can be unlocked by integrating S3V's devices into government reimbursement programs.
Sh. Rajesh Kumar Pathak: Secretary, TDB.
Dr. N.G. Vijaya Gopal: Managing Director of Ms S3V Vascular Technologies Ltd.
Asia: Target market for S3V Vascular Technologies.
Latin America: Target market for S3V Vascular Technologies.
Europe: Target market for S3V Vascular Technologies.
USA: Target market for S3V Vascular Technologies.
NKRPSM: Acronym associated with the release ID of the document.
CE: Regulatory approval that S3V is pursuing.
USFDA: Regulatory approval that S3V is pursuing.
Ministry of Science & Technology
“TDB-DST supports Breakthrough in Stroke Care:
Backs India’s First Indigenous Thrombectomy Device
by S3V Vascular Technologies”
“TDB-DST Funds India's First Neuro-Intervention
Integrated Manufacturing Plant for Stroke Treatment”
Posted On: 30 MAY 2025 5:25PM by PIB Delhi
In a significant boost to India's medtech innovation landscape, the Technology Development Board (TDB),
Department of Science and Technology (DST), has extended financial support to M/s S3V Vascular
Technologies Limited, Mysuru, for their project titled “Integrated Manufacturing of Mechanical
Thrombectomy Kit for Treatment of Acute Ischemic Stroke.” The board has sanctioned assistance to this
pioneering initiative aimed at transforming stroke treatment through indigenous innovation.
The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the
Medical Devices Park, Oragadam, Sriperumbudur (Chennai), to develop and manufacture advanced
mechanical thrombectomy kits—a life-saving intervention for patients suffering from acute ischemic stroke
due to large vessel occlusion. Compared to conventional thrombolysis, thrombectomy offers significantly
improved outcomes, reducing the risk of long-term paralysis and disability. Thus making a difference between
“PARALYSIS and RECOVERY”
S3V Vascular Technologies is set to become the first Indian company to indigenously design and manufacture
the complete suite of neuro-intervention devices, including microcatheters, aspiration catheters, guidewires,
and stent retriever systems in an upstream integrated facility. The company also intends to file patents for
critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and
several advanced process technologies.
By replacing expensive imported devices with high-quality, locally manufactured alternatives, this initiative is
poised to enhance both affordability and accessibility of stroke care in India. The company aims to integrate
these devices into government reimbursement programs such as Ayushman Bharat, thereby unlocking adomestic market estimated at 2 Billion USD. As part of its outreach, S3V also plans to collaborate with
leading hospitals to offer simulator-based training for young interventionalists—especially in Tier-II cities,
where the stroke burden is high.
Speaking on the occasion, Sh. Rajesh Kumar Pathak, Secretary, TDB, said “TDB is proud to support S3V’s
vision of building India’s first comprehensive neuro-intervention manufacturing ecosystem. This project
reflects our continued commitment to making India a global hub for affordable, high-end medical
technology—especially in areas of critical public health need like stroke care. The company’s focus on
integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare
access.”
Commenting on the support, Dr. N.G. Vijaya Gopal, Managing Director of M/s S3V Vascular Technologies
Ltd. Said “With Technology Development Boards’ backing, we are setting a new benchmark in indigenous
MedTech manufacturing. Our integrated manufacturing facility will not only reduce dependency on imports
of the finished medical devices used in Mechanical Thrombectomy but also reduces Indias dependency on
import of the raw materials used in manufacturing of these critical complex lifesaving medical devices. We
have initiated the CE and USFDA approval process for these devices to expand our access to cutting-edge
stroke care solutions across India, Asia, Latin America, Europe and USA. We’re committed to delivering
world-class innovation—designed, engineered, and made entirely in India to the World.”
****
NKR/PSM
(Release ID: 2132783)